Page last updated: 2024-12-06
cryptopine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Cryptopine is an alkaloid found in the opium poppy (Papaver somniferum) and other plants. It is a potent inhibitor of the enzyme monoamine oxidase (MAO) and has been shown to have a variety of pharmacological effects, including antidepressant, anti-inflammatory, and anti-cancer activity. Cryptopine is also known to interact with the opioid receptors in the brain, leading to analgesic effects. Due to its complex structure and pharmacological properties, cryptopine has been the subject of numerous research studies, focusing on its potential therapeutic applications. For example, studies have investigated its efficacy in treating depression, inflammation, and cancer. The synthesis of cryptopine involves complex organic chemistry reactions and has been studied extensively to understand its structure and reactivity. Cryptopine is a fascinating molecule with a rich history and ongoing research potential.'
cryptopine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 72616 |
| CHEMBL ID | 1339015 |
| SCHEMBL ID | 178039 |
| MeSH ID | M0050169 |
Synonyms (43)
| Synonym |
|---|
| kryptocavin |
| cryptocavine |
| kryptopine |
| cryptopin |
| mls000737655 , |
| nsc-32984 |
| NSC32984 , |
| benzo[e]-1,5-l][2]benzazecin-12(5h)-one, 4,6,7,13-tetrahydro-9,10-dimethoxy-5-methyl- |
| cryptopine |
| 482-74-6 |
| smr000386998 |
| MLS001048981 |
| brn 0354948 |
| 12,13,14,15,-tetrahydro-9,10-dimethoxy-14-methylbenzo(e)-1,3-dioxolo(4,5-1)(2)benzazecin-7(6h)-one |
| benzo(e)-1,3-dioxolo(4,5-l)(2)benzazecin-12(5h)-one, 4,6,7,13-tetrahydro-9,10-dimethoxy-5-methyl- |
| nsc 32984 |
| einecs 207-584-8 |
| NCGC00017386-01 |
| tnp00336 |
| OPREA1_763951 |
| NCGC00142563-01 |
| NCGC00142563-02 |
| AKOS002141588 |
| 2,3-dimethoxy-13-methyl-12,13,14,15-tetrahydro[1,3]benzodioxolo[4,5-c]benzo[g]azecin-5(6h)-one |
| CHEMBL1339015 |
| NCGC00017386-03 |
| NCGC00017386-02 |
| HMS2268G15 |
| unii-mw13x5yk4a |
| mw13x5yk4a , |
| 4-27-00-06652 (beilstein handbook reference) |
| SCHEMBL178039 |
| cryptopine [mi] |
| 4,6,7,13-tetrahydro-9,10-dimethoxy-5-methylbenzo(g)-1,3-benzodioxolo(4,5-c)azecin-12(5h)-one |
| W-202849 |
| DTXSID40197463 |
| 11,12-dimethoxy-7-methyl-6,8,9,15-tetrahydro[1,3]benzodioxolo[4,5-c]benzo[g]azecin-14(7h)-one |
| FT-0701441 |
| Q1142307 |
| 6,7-dimethoxy-12-methyl-16,18-dioxa-12-azatetracyclo[12.7.0.04,9.015,19]henicosa-1(14),4,6,8,15(19),20-hexaen-3-one |
| STL561433 |
| 482-74-6 (free base) |
| 11,12-dimethoxy-7-methyl-6,8,9,15-tetrahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-c]benzo[g]azecin-14(7h)-one |
Research Excerpts
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cryptopine has also been recovered from the mother liquor after the separation of thebaine." | ( Recovery of thebaine and cryptopine from Indian opium. Chandra, P; Ramanathan, VS, 1980) | 1.29 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to evaluate the effect of repeated oral administration of cryptopine at differential dosing regimens (50, 100, 150, 200 mg/kg bwt) in vivo on lipid peroxide measures, glutathione levels (GSH) and activity of glutathione S-transferase (GST) and glutathione reductase (GR) in the liver, spleen, kidney and lung of Male Wistar rats after a 5 day treatment period." | ( Stimulation of lipid peroxidation and impairment of glutathione-dependent defense system in Wistar rats treated with cryptopine, a rare non-narcotic opium alkaloid. Aneja, R; Chandra, R; Katyal, A, ) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (5)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 39.8107 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 141.2540 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 0.0251 | 0.0020 | 7.5337 | 39.8107 | AID891 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 10.0000 | 0.0025 | 5.8400 | 31.6228 | AID899 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Bioassays (17)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID592712 | Inhibition of GST-tagged Rad9/recombinant human N-terminal domain of RPA70 DNA binding domain interaction by electrophoretic mobility shift assay | 2011 | Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8 | Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6 | A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (26.67) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 55.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (55.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||